MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Lpath, Inc. (LPTN) Issued Patent Related To Ocular Drug Program ISONEP 0 comments
    May 30, 2013 4:09 PM | about stocks: LPTN

    Lpath is a therapeutic antibody company and the category leader in lipid-targeted therapeutics. The company ImmuneY2 drug discovery engine has the unique ability to generate monoclonal antibodies that bind to and inhibit bioactive lipids that contribute to disease. Lpath has three drug candidates currently: Lpathomab, ASONEP, and iSONEP.

    The company announced today that it has received official notification from the U.S. Patent and Trademark Office that it has been issued a key patent supporting its iSONEP program. The new patent claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet AMD (age-related macular degeneration). The company has a similar patent in Europe.

    Lpath is currently conducting a Phase II clinical trial for iSONEP, called Nexus, which is evaluating the anti-S1P antibody's safety and efficacy in wet-AMD patients. In 2010, the company entered into an agreement with drug giant Pfizer that provides Pfizer an exclusive option for worldwide license to develop and commercialize iSONEP.

    The company is also conducting a Phase II trial for ASONEP in renal cell carcinoma patients. Both iSONEP and ASONEP are formulations of sonepcizumab, a first-in-class therapeutic antibody against S1Pdeveloped using Lpath's ImmuneY2. Antibodies developed using this discovery engine are designed to target bioactive signaling lipids that are involved in cancer, macular degeneration, and many other diseases.

    For further information about Lpath, its ImmuneY2 discovery engine, and its drug candidates, please visit www.Lpath.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: LPTN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.